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Abstract
Background Patients with b-thalassaemia major experience
chronic iron overload due to regular blood transfusions.
Chronic iron overload can be treated using iron-chelating
therapies such as desferrioxamine (DFO), deferiprone
(DFP) and deferasirox (DFX) monotherapy, or DFO–DFP
combination therapy.
Objectives This study evaluated the relative cost effec-
tiveness of these regimens over a 5-year timeframe from a
UK National Health Service (NHS) perspective, including
personal and social services.
Methods A Markov model was constructed to evaluate
the cost effectiveness of the treatment regimens over
5 years. Based on published randomized controlled trial
evidence, it was assumed that all four treatment regimens
had a comparable effect on serum ferritin concentration
(SFC) and liver iron concentration (LIC), and that DFP was
more effective for reducing cardiac morbidity and mor-
tality. Published utility scores for route of administration
were used, with subcutaneously administered DFO
assumed to incur a greater quality of life (QoL) burden than
the oral chelators DFP and DFX. Healthcare resource use,
drug costs (2010/2011 costs), and utilities associated with
adverse events were also considered, with the effect of
varying all parameters assessed in sensitivity analysis.
Incremental costs and quality-adjusted life-years (QALYs)
were calculated for each treatment, with cost effectiveness
expressed as incremental cost per QALY. Assumptions that
DFP conferred no cardiac morbidity, mortality, or mor-
bidity and mortality benefit were also explored in scenario
analysis.
Results DFP was the dominant strategy in all scenarios
modelled, providing greater QALY gains at a lower cost.
Sensitivity analysis showed that DFP dominated all other
treatments unless the QoL burden associated with the route
of administration was greater for DFP than for DFO, which
is unlikely to be the case. DFP had [99 % likelihood of
being cost effective against all comparators at a willing-
ness-to-pay threshold of £20,000 per QALY.
Conclusions In this analysis, DFP appeared to be the
most cost-effective treatment available for managing
chronic iron overload in b-thalassaemia patients. Use of
DFP in these patients could therefore result in substantial
cost savings.
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Key Points for Decision Makers
• Deferiprone (DFP) is the dominant treatment strategy
for removal of excess iron in b-thalassaemia patients
in the base case, meaning that it provides additional
benefits over comparator treatments at a cost saving
to the NHS.
• DFP remains the dominant strategy against all com-
parators in a number of different modelling scenarios,
in which it is assumed that DFP significantly reduces
cardiac morbidity only, significantly reduces cardiac
mortality only, or confers no cardiac benefit.
• Probabilistic sensitivity analysis demonstrates that, at
a willingness-to-pay threshold of £20,000 per QALY,
DFP has a [99 % likelihood of being cost effective
against all comparators.
1 Introduction
Thalassaemia is one of the most common genetic diseases
worldwide, with approximately 60,000 severely affected
children born each year [1]. Children born with the
b-thalassaemia major form of the disease suffer chronic
severe anaemia and require blood transfusions every
2–4 weeks to sustain life [2–5]. It has been estimated that
this form of the disease affects 1 in 100,000 of the UK
population [3], and that approximately 700 patients with
b-thalassaemia major were alive in the UK in 2003 [6]. As
a result of repeated transfusions, these patients accumulate
iron at a rate of 0.3–0.5 mg/kg per day. This results in a
60 kg person adding 6.6–11.0 g of extra iron per year every
year for the rest of their life. In contrast, healthy adults
have stable iron stores of around 3–4 g [7]. Beta-thalas-
saemia major patients receiving regular transfusions are
consequently at risk of iron overload, which can cause
hypogonadism, hypothyroidism, diabetes mellitus, liver
dysfunction and heart dysfunction [8, 9]. If left untreated,
patients are at risk of premature death in adolescence or
young adulthood, mainly due to iron-induced cardiac dis-
ease [10].
The standard treatment for transfusional iron overload is
chelation therapy, which has significantly reduced mortal-
ity since the introduction of desferrioxamine (DFO) in the
1960s [11]. However, DFO is administered as a subcuta-
neous (SC) infusion over 8–12 hours, 5–7 days per week
[12]. This can have a significant impact on patients’ quality
of life (QoL) [13] and sets younger patients apart from their
peers [5, 13]; adherence to the DFO infusion schedule is
therefore often resisted, significantly increasing patients’
risk of cardiac disease [14]. Oral chelation therapy has
subsequently been developed in order to ease the treatment
burden associated with iron chelation, and therefore
increase patient compliance. The introduction of the first
oral chelator, deferiprone (DFP), in 1999 [15] resulted in
improved patient survival [6, 16], while deferasirox (DFX)
was licensed in 2006 [17].
When used as monotherapy, each of DFO, DFP and
DFX have been shown to produce reductions in serum
ferritin concentration (SFC) and liver iron concentration
(LIC) [18–21]; however, these measures of total body iron
are not effective in predicting heart failure, the most seri-
ous consequence of iron toxicity. For this outcome, it has
been found that cardiac iron levels, as measured by cardiac
MRI T2*, have the greatest predictive value [22]. DFP has
been demonstrated to be superior to DFO in reducing
cardiac iron levels, and in improving cardiac function as
assessed by left and right ventricular ejection fraction
(LVEF and RVEF, respectively) [16, 19–21]. This is an
important finding, as improvements in LVEF have been
shown to significantly reduce the risk of future heart failure
[23]. DFP may also be used as a combination therapy with
DFO, which has been shown to significantly improve SFC,
LIC, cardiac MRI T2* and cardiac function, compared with
DFO alone [24–26]. DFX is contraindicated for use in
combination therapy [17].
The licensed indication for DFP in Europe is for patients
in whom DFO therapy is contraindicated or inadequate
[15]; however, use of DFP in monotherapy or in combi-
nation with DFO is widespread. This is likely due to sev-
eral factors, including the inadequacy of DFO in
controlling body iron load in some patients [27]; the sig-
nificant QoL burden associated with its daily administra-
tion [13, 28]; and the superiority of DFP to DFO in
reducing heart disease and/or increasing survival [15]. The
combination of DFO and DFP has the added advantage of a
more pronounced reduction of serum ferritin and liver iron
concentrations than DFO monotherapy [25].
With four treatment regimens available with differing
abilities to remove excess iron, different prices, and dif-
ferent treatment burdens, the relative cost effectiveness of
these treatments is highly relevant when considering which
treatment to prescribe. Previous economic evaluations have
focused on DFO and DFX, and have reported that DFX is
cost effective compared with DFO, although none have
used published adverse event (AE) rates [3, 28, 29]. How-
ever, DFP has been included in cost-effectiveness analysis
in only one study, from a Thai perspective, which did not
consider combination therapy [30]. While this study found
that DFP was cost effective compared with DFX and DFO,
the lack of a full economic evaluation of all available
treatment regimens from an EU member state with signifi-
cant use of the relevant chelators (for example, the UK) to
guide a European perspective may hinder decision makers.
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This study consequently considers the cost effectiveness
of DFO, DFP and DFX monotherapy, and combination
therapy, from a UK perspective, using a full economic
model which incorporates published treatment-related AE
rates. The effect of varying all parameters used within the
model was evaluated in sensitivity analysis.
2 Methods: Systematic Review
Systematic reviews were conducted to identify random-
ized controlled trial (RCT) and non-RCT characteristics
of iron chelation with each treatment, and quality of life
in patients receiving chelation therapy. Searches were
conducted in The Cochrane Library, OVID MEDLINE
(including MEDLINE In-process) and OVID Embase on
9 February 2011, with no restrictions on date. Using
Boolean operators, the searches combined terms
(including MeSH headings as appropriate) for the con-
dition, the treatments and the outcomes of interest. This
was supplemented by hand searching of the following
conference proceedings from the years 2008 to 2010:
American Society for Hematology; European Haema-
tology Association Congress; UK Thalassaemia Society;
Thalassaemia International Conference; British Society
for Haematology Annual Scientific Meeting; Caribbean
Health Research Council Meetings; and the National
Sickle Cell Disease Program Annual Meeting. Identified
studies were independently assessed by two reviewers in
order to confirm that they met the pre-defined inclusion/
exclusion criteria and any discrepancies were resolved
by a third party (see Acknowledgments). Each review-
er’s documents were checked by the second reviewer to
ensure quality and any inconsistencies were resolved
through discussion. The inclusion criteria for the sys-
tematic review were: population—thalassaemia patients
with chronic iron overload requiring blood transfusions;
intervention—DFP, DFO, DFX or combination therapy;
study design—RCT, prospective, or observational stud-
ies; outcomes—SFC, LIC, cardiac MRI T2*, total iron
excretion, mortality or AEs. Full details of the system-
atic review are available in the electronic supplementary
material.
3 Results: Systematic Review
A total of 4,053 publications were screened, based on their
title and abstract. From these, the full texts of 69 publica-
tions were evaluated, which yielded 11 relevant RCTs [18,
19, 25, 31–38] and 9 non-RCTs [16, 20, 21, 39–44]. These
publications were used to identify potential data inputs for
the model.
4 Methods: Economic Model
4.1 Outline of the Economic Model
4.1.1 Population, Perspective, and Comparators
The model considered adults and children, regardless of
treatment history or disease status, with transfusion-
dependent b-thalassaemia receiving iron chelation therapy
for chronic iron overload. The model used a UK National
Health Service (NHS) perspective (including personal and
social services), in line with UK health technology
appraisal (HTA) guidelines [45]. A societal perspective
was not used due to a lack of data on productivity gains/
losses or absenteeism with the available treatment regi-
mens. The comparators considered were DFO, DFX and
DFP monotherapy, and combination therapy with DFO–
DFP, with discounting at 3.5 % in line with guidance from
the UK Treasury [46].
4.1.2 Base Case
The base case for the model was a 5-year Markov-type
model using an annual cycle where it was assumed that
DFP-containing regimens confer an incremental benefit to
patients in terms of cardiac morbidity and mortality over
DFO or DFX monotherapy. A Markov structure was used
based on the relevant clinical data (cardiac mortality and
morbidity); this structure has been used in previous eco-
nomic evaluations of iron chelation regimens [29, 30]. An
annual cycle was chosen given the availability of annual
mortality data; such a cycle has also previously been used
in economic evaluations of iron chelation regimens [28].
Five years was chosen as the time horizon as this reflects
the duration of the clinical trials from which the data on
morbidity and mortality were derived. Model calculations
were verified by a local health economist and model
assumptions by two consultant haematologists and one
consultant nephrologist.
4.1.3 Scenarios Considered
The cardiac benefit in morbidity and mortality of DFP over
DFX is an assumption based on the available evidence (see
Sect. 4.2.1); three alternative efficacy-based scenarios were
therefore also considered using Markov-type models: the
base case excluding a cardiac morbidity benefit but main-
taining the mortality benefit over 5 years (Scenario 1)
(Fig. 1); the base case excluding a cardiac mortality benefit
but maintaining the cardiac morbidity benefit over 5 years
(Scenario 2); and a 1-year Markov-type model where all
treatments are assumed to have an equal effect on cardiac
morbidity and mortality (Scenario 3). The 1-year approach
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is used in Scenario 3 as this is consistent with other eco-
nomic evaluations which have assumed equal efficacy for
all treatments [3, 28]. As DFO patients may receive treat-
ment via a battery-operated pump instead of a balloon
infuser, a scenario was also considered where all DFO and
combination therapy patients received treatment via a
pump (Scenario 4).
4.1.4 Model Outcomes
The model calculated costs and quality-adjusted life years
(QALYs) for each treatment regimen based on the cost of
the regimen, the relative effect on cardiac morbidity and
mortality, the associated AEs and the utilities associated
with their route of administration. Cost per QALY was
chosen as the primary outcome as this accounts for the
quality and quantity of the health gain from a treatment
regimen, as well as the impact of that treatment regimen
upon patients’ quality of life.
4.1.5 Model Inputs and Assumptions
The data used to inform the model were obtained from a
systematic review of the literature and other relevant data
sources. The assumptions used in the model are given in
Table 1.
4.2 Data Used in the Model
4.2.1 Efficacy
A review of the results of the trials identified by the sys-
tematic review showed that DFO and DFP have a similar
effect on SFC and LIC [18, 19], and that DFO and DFX1
also produce equivalent results for these outcomes [31, 38].
Given the absence of RCTs directly comparing DFP and
DFX, it was assumed that DFP and DFX had an equivalent
effect on these outcomes, based on the equivalence of each
to DFO [18, 19, 31].
In the absence of direct evidence of the effect of a drug
on cardiac morbidity and mortality, cardiac MRI T2* was
used as a proxy. The relative risk (RR) of heart failure or
arrhythmia has been shown to increase linearly as T2*
times decrease from 20 ms [22]. Patients with a T2*\6 ms
consequently have a RR of heart failure of 270, and a RR
of arrhythmia of 8.79, compared with T2* C20 ms [22].
DFO and DFX have been shown to have a similar effect on
this outcome in observational studies [20, 21], and were
therefore assumed to have an equivalent effect on cardiac
mortality and morbidity. DFP-containing regimens (DFP
monotherapy and combination therapy) were found to
improve cardiac outcomes, compared with DFO mono-
therapy [16, 19–21]. As only one RCT reported mortality
for DFP monotherapy, data from the multi-centre, open-
label trial in 144 patients by Maggio et al. [34] were used to
model cardiac mortality. No RCTs reported on morbidity
for DFP; a retrospective analysis in 129 patients by Piga
et al. [43] comparing DFP with DFO was therefore used to
model cardiac morbidity. The data from Piga et al. for this
outcome are consistent with those from another observa-
tional study by Borgna-Pignatti et al. [16].
Maggio et al. reported no deaths in the DFP and com-
bination therapy groups, and 4.8 % cardiac mortality in the
DFO group over 5 years, while Piga et al. reported 4 %
morbidity in the DFP group and 21 % in the DFO group
over 5 years. These were converted into an annual rate for
use in the model using actuarial life-table methods2 [47].
Base case: Cardiac mortality and morbidity benefit for DFP
Dead
Alive without cardiac 
disease
Alive with cardiac 
disease
Scenario 1: Cardiac mortality benefit only for DFP
Alive without cardiac 
disease Dead
Scenario 2: Cardiac morbidity benefit only for DFP
Alive without cardiac 
disease
Alive with cardiac 
disease
Fig. 1 Schematics of the Markov model used for each scenario. No
schematic is shown for Scenario 3, as in this scenario the patient is
alive without cardiac disease and remains in this state. DFP
deferiprone
1 The registration trial for DFX failed to meet the primary endpoint
of maintenance or reduction of LIC; however, this was attributed to
the fact that patients received proportionally lower doses of DFX
relative to DFO. The authors conclude that there was a clear
demonstration of iron excretion related to the dose administered [31].
2 Data were adjusted for use in the model by converting the 5-year
probability of the event into a 5-year rate, which was then adjusted to
an annual rate and converted back into an annual probability. This is
achieved using the following formula: 1 - EXP(-(-LN(1 - (Prob-
ability of event over time period considered, X))/(Time period
considered, X/Time period required, Y))).
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Lower and upper limits for sensitivity analysis were cal-
culated from standard errors (SE); for treatment arms with
zero events, the number of patients and events was
increased by 0.5 to create a SE which could be used to
estimate the upper limit. A summary of the values used in
the model is given in Table 2.
4.2.2 Adverse Events
Only AEs specifically mentioned as areas of concern within
the summaries of product characteristics (SPCs) [12, 15, 17]
that were also likely to impact upon healthcare costs and
quality of life were included in the model. While DFX has
been cited as a factor in a number of treatment-related
deaths across several disease areas [48], no quantitative data
were published on thalassaemia patients with transfusional
iron overload, and so it was conservatively assumed that
DFX was not associated with excess mortality.
DFP is associated with agranulocytosis and neutrope-
nia events, with the SPC quoting rates of 0.6 and 2.5 per
100 patient-years, respectively. These were converted
into annual rates of 0.6 and 2.5 % [15], respectively, with
an assumed agranulocytosis mortality rate of 13.83 %
[49]. The mortality rate for agranulocytosis is based on
post-marketing reporting of 13 deaths from 94 cases.
However, 11 of these deaths (from 45 cases) occurred
prior to the implementation of a physician and patient
education programme in 2007. Fewer deaths have
occurred since this time (2 deaths from 49 cases), and the
true mortality rate is likely to be less than that used in
the model [49].
DFX is associated with hepatitis and Fanconi syndrome,
with a hepatitis rate of 0.7 % assumed based on the DFX
prescribing information [50]. A specific rate for Fanconi
syndrome is not reported in the DFX prescribing infor-
mation; data from Yacobovich et al. [51] were therefore
used. It was conservatively assumed that the four cases
reported represented a minimum estimate of the rate for the
entire transfusion-dependent thalassaemia population
requiring iron chelation for that country (estimated at 500)
[51]. This is consistent with the prescribing information for
DFX, which lists Fanconi syndrome as an uncommon AE
(\1 %) [50].
While DFO is associated with neutropenia, in the
absence of published rates it was conservatively assumed
that DFO was not associated with any AEs. Due to the lack
of appropriate data on AEs with combination therapy, it
was assumed that the rate of AEs was equivalent to DFP
monotherapy. A summary of the values used in the model
is given in Table 2.
4.2.3 Utility Data
It was conservatively assumed that all patients with cardiac
morbidity would have the mildest form (New York Heart
Association [NYHA] class I). A utility score of 0.921 was
calculated for this stage based on an average of utility
values identified by searching the TUFTS cost-effective-
ness analysis registry [52]. As the baseline utility for
NYHA I is above the baseline values for chelation thera-
pies, a proportional decrement was calculated and applied
to the utility value for chelation (7.9 % decrement from
Table 1 Assumptions used in the model
Patient weight of 63 kg, based on the average weight for men and women calculated from the British National Formulary and varied within
the sensitivity analysis to account for a spectrum of child and adult weights [56]. This weight is consistent with the average patient weight
from US DFP patient registries of 62 kg [57]
Dosing was assumed to be from the mid-range of the product SPCs, based on the input of two consultant haematologists and one consultant
nephrologist. The impact of alternative dosing was considered in sensitivity analysis
Patients who developed cardiac disease were conservatively assumed to have NYHA grade I disease and no incremental costs were
considered
The cost of managing thalassaemia was assumed to be the same for all treatment regimens and was therefore not accounted for in the model
All iron chelation regimens are assumed to have an equivalent effect on SFC and LIC. Given the difficulty in correlating these outcomes with
morbidity and mortality, this assumption was not varied in sensitivity analysis
Due to a lack of data regarding the efficacy of DFX in cardiac morbidity and mortality, it was assumed that the rates of cardiac events
(including deaths with DFX) are the same as for DFO. Data on cardiac T2* for DFO and DFX were used as a proxy to establish equivalence
of the treatments
As morbidity and mortality data are taken from separate studies, the risk of death in both alive health states was considered to be equal
The utility value for DFP administration was assumed to be equal to that for DFX based on oral administration dosing regimens
While compliance is expected to be greater with oral treatments than with SC infusion, RCTs have found no difference [19, 21]. In the
absence of robust data indicating a difference between treatments, compliance was assumed to be comparable across all regimens
DFO desferrioxamine, DFP deferiprone, DFX deferasirox, LIC liver iron concentration, NYHA New York Heart Association, RCT randomised
controlled trial, SC subcutaneous, SFC serum ferritin concentration, SPC summary of product characteristics
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perfect health). A summary of the values used in the model
is given in Table 2.
Utility scores for each AE were obtained from the
published literature [53–55], with the duration for which
the decrement was applied based on the expert opinion of
two consultant haematologists and one consultant
nephrologist. As no published utility scores for Fanconi
syndrome exist, it was conservatively assumed that the
condition has no impact on quality of life. The utility
values, event duration and decrement from perfect health
used in the model are given in Table 2.
The effect of the administration of iron chelation ther-
apy on quality of life has been examined by Karnon et al.
[28] using a time-trade-off method. This study estimated a
Table 2 Values used in the model
Source data Value used in the model Variation in sensitivity
analysis (upper, lower)
Assumptions
Patient weight Average weight of men/women
from BNF [56]




Non-RCT; 4 % over 5 years [43] 4 % 0.00, 9.23b
Cardiac morbidity—DFO/DFX Non-RCT; 21 % over 5 years [43] 21 % 11.78, 30.22b
Cardiac mortality—DFP/
combination therapy
RCT: 0 deaths over 5 years [34] 0 % at 5 years 0, 2.49b
Cardiac mortality—DFO/DFX RCT: 4.8 % mortality over
5 years [34]
4.8 % at 5 years 1.58, 9.71b
Utility associated with cardiac
morbidity
0.921 [52] 7.9 % decrement applied to the utility





Product SPC: 0.6 per 100 patient-
years [15]
Annual rate of 0.6 % 0.21, 0.35c
DFP/combination therapy—
neutropenia
Product SPC: 2.5 per 100 patient-
years [15]
Annual rate of 2.5 % 1.88, 3.13c
DFX—hepatitis Product SPC: 0.7 % [17] 0.7 % 0.02 %, 1.58 %b
DFX—Fanconi syndrome Clinical case reports: 0.8 % [51] 0.8 % 0.02 %, 1.63 %c
DFO—no AEs – – –
Risk of mortality associated
with agranulocytosis
Post-marketing data: 13.83 % 13.83 % 6.85, 20.81b
Utility associated with AEs
Agranulocytosis Published model: 0.460 [54] 0.460 for 7 days, 54.0 % decrement
from perfect health
0.345, 0.575c
Neutropenia Published model: 0.782 [55] 0.782 for 1 day, 21.8 % decrement
from perfect health
0.587, 0.978c
Hepatitis Published model: 0.770 [53] 0.770 for 365 days, 23.0 % decrement
from perfect health
0.710, 0.810c
Fanconi syndrome No data available No impact on QoL No variation
Route of administration utility
Oral Prior economic evaluation:
0.840 [28]
0.840 0.66, 1.00d
SC infusion Prior economic evaluation:
0.660 [28]
0.66 for five times weekly DFO
0.696 for four times weekly combination
therapy
0.25b, 0.84d
AE adverse event, BNF British National Formulary, DFO desferrioxamine, DFP deferiprone, DFX deferasirox, QoL quality of life, RCT
randomized controlled trial, SC subcutaneous, SPC summary of product characteristics
a Reported in source. b Calculated based on standard error reported in source. c Calculated by varying the reported value ±25 %. d Calculated
value would be outside the plausible range, value set to plausible maximum (i.e., maximum SC infusion utility cannot be higher than the standard
oral utility, and the minimum oral utility cannot be lower than the standard SC infusion utility)
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utility score of 0.660 for SC DFO (administered five times
weekly) and 0.840 for oral DFX. When used in combination
therapy, DFO was assumed to be administered four times
weekly; the utility for combination therapy was therefore
the utility for DFX minus 80 % of the difference between
DFX and combination therapy (0.84 - ((0.84 - 0.66)
9 0.8) = 0.696). As no studies have assessed the compara-
tive utility scores of DFP and DFX, these treatments were
assumed to have the same utility score, as both are adminis-
tered orally. A summary of the values used in the model is
given in Table 2. AE and cardiac morbidity utilities were
applied as a proportional decrement of the utility associated
with the administration route for each treatment regimen, i.e.
the utility for a patient receiving DFX who developed
hepatitis was 0.840 - (0.23 9 0.840), rather than 0.840 -
0.230.
4.2.4 Cost Data
It was conservatively assumed that all patients with cardiac
morbidity would have the mildest form (NYHA I) and
would incur no costs as a consequence of this.
Drug acquisition costs for the latest year available for
each treatment (2010/2011) were obtained from the British
National Formulary [56]. The model assumes a crude
average price per mg across all dosages and formulations,
with the cost of DFO based on the generic drug in the base
case. Treatment costs per day and per year are presented in
Table 3, using an average male/female weight of 63 kg
[56] and a daily dose representing the mid-point from each
product SPC in the base case. This weight is consistent
with the average patient weight from US DFP patient
registries of 62 kg [57]. These values were varied in sen-
sitivity analysis within the dose ranges recommended in the
respective UK SPCs.
As DFP and DFX are given orally, administration costs
were applied to DFO only; these are summarized in
Table 4 for the base case where all patients are assumed to
use a balloon infuser. In Scenario 4, where DFO patients
are assumed to use a pump instead of balloon infuser, one
pump (£857.97) and 2.91 batteries (£306.66 each) replaced
the balloon infusers. Total administration costs for DFO
and combination therapy were therefore £2,441 and
£1,953, respectively. All administration cost data are based
on a previous economic evaluation by Karnon et al. [28],
inflated from 2005 to 2010/2011 prices using standard
inflation indices [58].
The monitoring tests required and frequency of testing
were applied according to the product SPCs and UK
Thalassaemia Society guidelines (Table 5) [5]. For com-
bination therapy, the rates for DFP testing have been
combined with those for DFO to provide a conservative
estimate. There is currently no national set NHS price list
for laboratory tests; all costs were therefore based on
internal costing exercises provided by the Quality Manager
at the Department of Laboratory Haematology at the John
Radcliffe Hospital, Oxford, unless specified (personal
communication).
The costs for managing treatment-related adverse events
were obtained from national sources [56, 59] and validated
by the expert opinion of two consultant haematologists and
one consultant nephrologist, except for hepatitis, where a
previous UK economic evaluation was used [60]. Esti-
mated costs were: £3,782 for agranulocytosis (Healthcare
Resource Group [HRG] code PA48a) [59]; £684 for neu-
tropenia (HRG code PA48a) [59]; £163 for Fanconi syn-
drome (30 days of treatment with sodium bicarbonate
capsules and phosphate tablets and one nephrologist con-
sultation, using the mid-point of reported resolution times
[51, 61–64]) [56, 59]; and £411 for hepatitis (3.3 consultant
Table 3 Treatment costs
Average cost/mg (£) Daily dose (mg/kg)a mg/Day Cost/day (£) Days of Tx/week (days of Tx/year)b Cost/year (£)
DFP
Ferriprox 0.0032 75.0 4,725 15.12 7 (365) 5,519
DFX
Exjade 0.0336 30.0 1,890 63.50 7 (365) 23,179
DFO
Generic DFO 0.0085 40.0 2,520 21.48 5 (260) 5,584
Combination therapy
Ferriprox 0.0032 75.0 4,725 15.12 7 (365) 5,519
Generic DFO 0.0085 40.0 2,520 21.48 4 (208) 4,467
Total cost – – – – 9,986
DFO desferrioxamine, DFP deferiprone, DFX deferasirox, Tx treatment
a Varied in sensitivity analysis around the upper and lower values reported in the source. b Varied in sensitivity analysis by ±25 %, or set to the
maximum value where variation exceeded the maximum
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appointments per year) [60]. These values were varied
±25 % in sensitivity analysis.
4.2.5 Sensitivity Analysis
Uncertainty surrounding the model inputs was assessed
through sensitivity analysis. One-way analyses were per-
formed using realistic minimum and maximum individual
model inputs and a tornado diagram was generated to
assess the main drivers of cost effectiveness. The effect of
different dosing regimens was assessed in a two-way sen-
sitivity analysis. In addition, all parameters were simulta-
neously varied in a probabilistic sensitivity analysis. Costs,
patient weights, and doses were assumed to follow gamma
distributions, while utilities and probabilities were assigned
beta distributions, in line with best practice [65, 66]. All
model inputs, with the exception of drugs with fixed prices,
were varied in sensitivity analysis.
5 Results: Economic Model
5.1 Base Case
The costs and QALYs associated with the different iron
chelation regimens per patient over a 5-year period are
presented in Table 6. DFP has the lowest overall cost of all
the treatment options and the highest QALY gain, and is
therefore the dominant treatment strategy. DFX produced a
higher QALY gain than both combination therapy and
DFO, but at a greater total cost, giving incremental cost-
effectiveness ratios (ICERs) of £36,141 and £42,923,
respectively. The ICER for combination therapy compared
with DFO was £59,093.
5.2 Scenario 1—Cardiac Mortality Only
This scenario conservatively assumed that there is no dif-
ference in cardiac morbidity between treatments and con-
siders only the impact of cardiac mortality. DFP again
resulted in greater QALY gains and cost savings than all
other treatments (Table 6), and is therefore the dominant
strategy in this scenario. The ICERs for DFX versus
combination therapy and DFO were £34,817 and £42,635,
respectively, while the ICER for combination therapy
versus DFO was £63,394.
5.3 Scenario 2—Cardiac Morbidity Only
This scenario assumed that there is no difference between
treatments for cardiac mortality and only considers cardiac
morbidity. DFP was again the dominant strategy, resulting
in greater QALY gains and cost savings than all other
treatments (Table 6). The ICERs for DFX versus combi-
nation therapy and DFO were £35,229 and £42,923,
respectively, while the ICER for combination therapy
versus DFO was £70,174.
5.4 Scenario 3—1-Year Model
This scenario conservatively assumed that there is no dif-
ference between treatments with respect to cardiac mor-
bidity or mortality. A 1-year time horizon was used; costs
were therefore not discounted in this scenario. DFP was the
dominant treatment strategy, resulting in greater QALY
gains (although this was marginal) and cost savings than all
other treatments (Table 7). The ICERs for DFX versus
combination therapy and DFO were £34,161 and £42,701,
respectively, while the ICER for combination therapy
versus DFO was £76,605.
5.5 Scenario 4—DFO Administered by Battery-
Operated Pump
This scenario assumed that all DFO patients received
treatment via a pump instead of a balloon infuser. DFP was
the dominant treatment, resulting in greater QALY gains
and cost savings than all other treatments (Table 7). The
ICERs for DFX versus combination therapy and DFO were









Balloon infuser 34.61 100 260 8,999
Portacath 288.69 5 0.5 7
Needles for portacath 4.59 5 300 69
Portacath surgery 1,128.03 5 0.5 28
Syringes 0.13 100 55.4 7
Needles 0.06 100 300a 17
Infusion sets 1.30 100 171.2a 222
Tape 0.74 100 10 7
Alcohol pads 0.04 100 310.9b 14
Gauze 0.03 100 300 10
Sharps bins 1.49 100 2 3
Home delivery costs 306.66 100 1 307
Total cost 9,690c
All values were varied ±25 % in sensitivity analysis using a gamma
distribution, with the exception of those marked a or b. Where this
variation exceeded the maximum plausible value, the maximum/
minimum limit was used. aValue was varied in sensitivity analysis
based on data reported in the source (0.00, 253.95). bValue was varied
in sensitivity analysis based on data reported in the source (0.00,
369.75). cThe cost applied to combination therapy was adjusted to
80 % of this value as DFO was assumed to be given four times
weekly
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£83,385 and £83,770, respectively, while the ICER for
combination therapy versus DFO was £84,687.
5.6 Sensitivity Analysis
5.6.1 One-Way Sensitivity Analysis
The results of the sensitivity analysis, comparing DFP with
each of the other treatment options, are represented in
tornado diagrams in Fig. 2, where the vertical line repre-
sents the base-case ICER. A negative figure on the x-axis
(i.e. \£0) indicates that DFP is the dominant treatment
strategy. For DFP versus DFX, no parameter variations
resulted in an ICER C£0, indicating that DFP was the
dominant strategy in all plausible scenarios. For DFP ver-
sus DFO or combination therapy, the main drivers of cost
effectiveness were the utility values associated with the
route of administration. DFP always remained the domi-
nant strategy when varying these utilities; while the ICER
tends to infinity when the utility of administration is equal,
DFP remains the least expensive treatment option.
5.6.2 Two-Way Sensitivity Analysis
Two-way sensitivity analyses were performed to assess the
impact of varying the administered dose of DFP compared
with the other treatment options. DFP remained the dom-
inant treatment strategy irrespective of the dose
comparison.
5.6.3 Probabilistic Sensitivity Analysis
This analysis was performed to account for parameter
uncertainty. Cost-effectiveness planes for DFP versus the




a All test frequencies were
varied around the maximum and
minimum values reported in the
source data. bAll costs based on
personal communication, except
audiometry (National Tariff for






contact, treatment function 130
[69]). cVaried ±25 % in
sensitivity analysis. dVaried in
sensitivity analysis based on
values reported in an alternative
source [70]. eThe summary of
product characteristics for DFP
states that monitoring should be
performed 4–6 times per year











Neutrophil count 52.00 3.47 2.61c, 15.50d 180.68
Serum zinc 4.00 10.28 7.71c, 38.75d 41.12
Ferritine 12.00 3.47 2.61c, 44.10d 41.17
Total monitoring cost/year 263.50
DFX
Serum creatinine (year 1) 15.00 1.51 1.13c, 14.30d 22.67
Serum creatinine
(subsequent years)
12.00 1.51 1.13c, 14.30d 18.13
Liver function (year 1) 15.00 1.60 1.20c, 17.88d 24.06
Liver function (subsequent
years)
12.00 1.60 1.20c, 17.88d 19.24
Urinalysis (year 1) 15.00 1.94 1.46c, 2.43c 29.14
Urinalysis (subsequent years) 12.00 1.94 1.46c, 2.43c 23.32
Audiometry 1.00 61.00 45.75c, 76.25c 61.00
Ophthalmology 1.00 67.00 50.25c, 73.75c 67.00
Ferritin 12.00 3.47 2.61c, 44.10d 41.70




Audiometry 4.00 61.00 45.75c, 76.25c 244.00
Ophthalmology 4.00 67.00 50.25c, 73.75c 268.00
Ferritin 4.00 3.47 2.61c, 44.10d 13.90
Total monitoring cost/year 525.90
DFO–DFP combination
Neutrophil count 52.00 3.47 2.61c, 15.50d 180.68
Serum zinc 4.00 10.28 7.71c, 38.75d 41.12
Ferritin 12.00 3.47 2.61c, 44.10d 41.70
Audiometry 4.00 61.00 45.75c, 76.25c 244.00
Ophthalmology 4.00 67.00 50.25c, 73.75c 268.00
Total monitoring cost/year 775.50
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other comparators, plotting the incremental costs and
QALYs for DFP versus each chelator in the base-case
scenario, are shown in Fig. 3. DFP was the most cost-
effective treatment option in all scenarios. The likelihood
of DFP being cost effective at a willingness-to-pay
threshold of £20,000 per QALY was: base case, 99.86 %;
scenario 1, 99.86 %; scenario 2, 99.84 %; scenario 3,
99.82 %; scenario 4, 99.34 %.
6 Discussion
A de novo health economic model was developed to assess
the cost effectiveness of DFP monotherapy compared with
DFX and DFO monotherapy or DFO–DFP combination
therapy. Published RCT evidence suggests that all chelators
have a similar, or minimally different, effect on LIC and
SFC levels [18, 19, 31]. DFP has been shown to be more
effective for reduction of excess cardiac iron and in reducing
cardiac mortality and morbidity compared with DFO
monotherapy, as reported in the SPC for DFP [15]. Com-
bination therapy has also been shown to be more effective
than DFO monotherapy in reducing SFC, LIC and cardiac
iron levels [24, 25]. However, the correlation between a
reduction in SFC or LIC and cardiac morbidity and/or
mortality is weak, with only cardiac iron levels shown to
have a high predictive value [22]. Therefore, only reductions
in cardiac iron levels were considered to have an impact on
cardiac mortality and morbidity; reductions in SFC and LIC
were assumed to have no effect on these outcomes.
The magnitude of cardiac iron reduction was compara-
ble in separate RCTs by the same lead investigator for DFP
versus DFO and combination therapy versus DFO [19, 25].
Equivalent efficacy regarding LIC and SFC was therefore
Table 6 Base-case analysis


















25,775 0 1,231 186 27,191 3.918
(27,577) (0) (1,317) (199) (29,093) (4.192)
DFO (Generic) 25,602 44,429 2,411 0 72,442 3.006 45,251 -0.912 Dominated
(27,374) (47,505) (2,578) (0) (77,457) (3.213) (48,364) (-0.979) Dominated
Combination
therapy
46,636 36,203 3,622 186 86,647 3.246 14,205 0.240 59,093
(49,898) (38,736) (3,875) (199) (92,708) (3.473) (15,251) (0.260) (58,664)
DFX (Exjade) 106,272 0 1,071 19 107,363 3.819 20,716 0.573 36,141
(113,629) (0) (1,145) (20) (114,795) (4.083) (22,087) (0.610) (36,224)
a Costs and QALYs are discounted at a rate of 3.5 %, in line with UK Treasury guidelines
AE adverse events, DFO desferrioxamine, DFP deferiprone, DFX deferasirox, ICER incremental cost-effectiveness ratio, Inc. incremental, QALY
quality-adjusted life year
Table 7 Scenario 1–4
Discounted valuea (undiscounted value)
Scenario 1 Scenario 2 Scenario 3b Scenario 4
Total costs (£) QALYs Total costs (£) QALYs Total costs (£) QALYs Total costs (£) QALYs
DFP (Ferriprox) 27,191 3.923 27,191 3.918 5,822 0.840 27,191 3.918
(29,093) (4.197) (29,093) (4.192) (29,093) (4.192)
DFO (Generic) 72,422 3.026 73,836 3.064 15,800 0.660 39,210 3.006
(77,457) (3.235) (79,001) (3.277) (41,924) (3.213)
Combination therapy 86,647 3.250 86,647 3.246 18,554 0.696 59,568 3.246
(92,708) (3.477) (92,708) (3.473) (63,734) (3.473)
DFX (Exjade) 107,363 3.845 109,428 3.893 23,429 0.839 107,363 3.819
(114,795) (4.111) (117,083) (4.164) (114,795) (4.083)
a Costs and QALYs are discounted at a rate of 3.5 %, in line with UK Treasury guidelines [46]. bNo discounting was applied in Scenario 3 as a
1-year horizon was used
DFO desferrioxamine, DFP deferiprone, DFX deferasirox, QALY quality-adjusted life year
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assumed in the model for DFO, DFX, DFP and combina-
tion therapy, with a cardiac benefit assumed for DFP-
containing regimens over DFO and DFX. Dosing
assumptions were daily administration for DFP and DFX,
while DFO was administered five times weekly, or four
times weekly when given in combination with daily DFP.
In order to obtain a realistic view of the cost effective-
ness of the agents of interest, the model also included AEs.
Common AEs indicated in product SPCs which were likely
to have an impact on patient quality of life and/or cost
implications were included. The AE assessment was lim-
ited by the availability and quality of reporting of AEs




(1.06% to 8.62%; base case 4.84%)
DFX: Daily dose
(50.00 to 10.00; base case 30.00)
Cardiac mortality at Yr5: DFP
(2.49% to 0.00%; base case 0.00%)
Utility: NYHA I
(1.00 to 0.82; base case 0.92)
% of pts with cardiac disease: DFX
(11.78% to 30.22%; base case 21.00%)
DFP: Daily dose
(50.00 to 100.00; base case 75.00)
Estimated average weight
(68.00 to 58.00; base case 63.00)
Rate of adverse event - Hepatitis: DFX
(0.00% to 1.63%; base case 0.70%)
% of pts with cardiac disease: DFP
(9.23% to 0.00%; base case 4.00%)
DFP: Tx per annum
(273.75 to 365.00; base case 365.00)
-£2,500,000 -£2,000,000 -£1,500,000 -£1,000,000 -£500,000 £0
-£100,000 -£50,000 £0 £50,000 £100,000 £150,000
Utility: Route of administration - Oral
(1.00 to 0.51; base case 0.84)
Utility: Route of administration - Infusion
(0.25 to 1.00; base case 0.66)
Generic DFO: Daily dose
(50.00 to 20.00; base case 40.00)
DFP: Daily dose
(50.00 to 100.00; base case 75.00)
% of pts: Balloon infuser - 100% BI
(100.00% to 75.00%; base case 100.00%)
Cardiac mortality at Yr5: DFO
(1.06% to 8.62%; base case 4.84%)
DFP: Tx per annum
(273.75 to 365.00; base case 365.00)
Monitoring costs: Neutrophil count
(£2.61 to £15.50; base case £3.47)
Cardiac mortality at Yr5: DFP
(2.49% to 0.00%; base case 0.00%)
Utility: NYHA I
(1.00 to 0.82; base case 0.92)
-£200,000 -£150,000 -£100,000 -£50,000 £0 £50,000 £100,000 £150,000 £200,000
Utility: Route of administration - Oral
(1.00 to 0.51; base case 0.84)
Utility: Route of administration - Infusion
(0.25 to 1.00; base case 0.66)
DFP: Daily dose
(50.00 to 100.00; base case 75.00)
Unit cost: Balloon infuser
(£43 to £26; base case £35)
Cardiac mortality at Yr5: DFP & DFO combination
(0.00% to 7.39%; base case 0.00%)
DFP: Tx per annum
(273.75 to 365.00; base case 365.00)
Combo: DFP - Tx per annum
(365.00 to 273.75; base case 365.00)
Cardiac mortality at Yr5: DFP
(2.49% to 0.00%; base case 0.00%)
Estimated average weight
(68.00 to 58.00; base case 63.00)
Combo: Generic DFO - Tx per annum
(156.00 to 365.00; base case 208.00)
Fig. 2 Tornado diagrams for
the sensitivity analyses of DFP
vs a DFX, b DFO, and




NYHA New York Heart
Association, Tx treatment
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within the clinical studies, which were varied in sensitivity
analysis to assess the impact of uncertainty.
The model base-case results suggest that DFP mono-
therapy is the dominant strategy (more effective and less
costly), compared with DFX and DFO monotherapy or
combination therapy. DFP is associated with 5-year cost
savings of £80,172 per patient relative to DFX, £45,251 per
patient relative to DFO and £59,456 per patient relative to
combination therapy. DFX was not cost effective relative
to DFO combination therapy or monotherapy (£36,141/
QALY and £59,093/QALY, respectively). Although com-
bination therapy was less costly than DFX, it had a lower
QALY gain due to the lower utility score associated with
SC administration of DFO, placing combination therapy in
the south-west quadrant of the cost-effectiveness plane.
However, it should be considered that oral DFX has no
proven cardiac morbidity or survival benefit over other
treatment regimens, while combination therapy has been
demonstrated to have benefits in terms of both cardiac
morbidity and survival [42]. DFP monotherapy remained
dominant in all scenarios, including a scenario where the
cardiac benefits of the drug were excluded and all iron
chelators were assumed to have the same efficacy. In this
case, the time horizon was assumed to be 1 year, with DFP
treatment resulting in a cost saving of £17,607 per patient
relative to DFX.
The model used in this analysis is conservative in many
of its assumptions, including AE rates for comparators,
costs of AE rates, grade of cardiac disease applied to
patients developing cardiac disease, and the compliance
rate (which was assumed to be equal across all therapies).
The majority of these assumptions bias the results against
DFP. For example, we have conservatively assumed that
DFX-induced Fanconi syndrome is not associated with a
decrement in quality of life, and that only one outpatient
nephrology appointment would be associated with its
management. Furthermore, we have not considered the
possibility that patients treated with DFX would develop
either acute or chronic renal failure. However, the DFX
SPC states that some patients within post-marketing studies
developed renal failure requiring temporary or permanent
renal dialysis [17]. Given that renal failure has a significant
impact on patient quality of life, and that the annual cost of
renal dialysis is likely to exceed £8,000 (based on the
average cost of haemodialysis from NHS reference costs)
[59], our model likely underestimates the true costs asso-
ciated with DFX therapy.
As with any economic evaluation, the current model has
limitations. It was necessary to make assumptions around
efficacy based on a systematic review of the literature; such
a review can only include data up to a specified time (in
this case, 9 February 2011). It will therefore be necessary
to re-evaluate the findings from this study as the evidence
evolves. No full published studies reporting the long-term
cardiac effects of DFX were identified by the systematic
review; it was therefore necessary to use proxy data in
order to develop assumptions surrounding this outcome.

























Vs. Combination Vs. DFO Vs. DFX
Fig. 3 Cost-effectiveness plane—incremental costs and effects for
DFP vs comparators. Each point represents a simulation, while the
dotted line represents the cost-effectiveness threshold (£20,000/
QALY); combination is DFO–DFP. DFO desferrioxamine, DFP
deferiprone, DFX deferasirox, QALY quality-adjusted life year
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long-term cardiac effects based on RCT data which indi-
cate that DFX is non-inferior to DFO in reducing cardiac
iron, as measured by T2*, with neither agent able to
improve cardiac function as assessed by LVEF [67]. This
assumption is further supported via non-RCT studies by
Pepe et al. [21] and Berdoukas et al. [20] that demonstrate
equivalent cardiac MRI T2* values between DFX and
DFO. Another possible limitation is the assumption of
equivalent efficacy regarding SFC and LIC for the three
iron chelators. No RCT studies exist which directly com-
pare DFP and DFX; it was therefore necessary to infer
similar efficacy via comparison with DFO, which was
found to have a similar effect on SFC and LIC when
compared with DFP or DFX [18, 19, 31]. It should be noted
that, while both studies comparing DFP and DFO found no
significant difference in SFC or LIC between the treat-
ments [18, 19], Pennell et al. [19] observed a non-signifi-
cant trend towards greater reduction of these assessments
with DFO. However, these potential differences in effect
on SFC and LIC between treatment regimens, even if they
had been statistically significant, were small and are unli-
kely to lead to an increase in complications in clinical
practice. The leading cause of death in thalassaemia
patients is cardiac-related complications, and small differ-
ences in SFC and LIC are not predictors of such events
[22]. In contrast, cardiac MRI T2* has been shown to have
a high predictive value for heart failure and a strong cor-
relation with iron-induced heart disease in studies by Kirk
et al. [22] and Carpenter et al. [68]. The limitations around
efficacy assumptions could be resolved by performing an
indirect comparison using the available trial data. Such an
evaluation was outside the scope of the current analysis,
but would be desirable for any future studies.
Other limitations include the use of cost per mg for each
regimen and the lack of national set NHS prices for labo-
ratory tests. Using cost per mg may be a limitation as this
assumes that tablets or vials may be halved or shared.
While this may not be the case in clinical practice, this is a
limitation inherent to the majority of economic models
using an average dose per patient. This is therefore unlikely
to have a significant impact upon the validity of the results.
Due to the lack of a national set NHS price list for labo-
ratory tests, it was necessary to use costs obtained through
internal costing exercises provided by the Quality Manager
at the Department of Laboratory Haematology at the John
Radcliffe Hospital, Oxford (personal communication).
These internal exercises are designed to provide the hos-
pital with a best estimate of the cost of laboratory tests,
based on variables including consumable use and personnel
costs. The John Radcliffe Hospital is a large UK institution;
as its estimated costs are likely to be comparable to those in
other similarly sized NHS trusts, it represents an appro-
priate source of information in the absence of set NHS
prices. While there is no guarantee that these costs are
generalizable, there is no evidence that they are not. These
costs also comprise only a small proportion of total costs
and therefore have a minimal effect on the model results.
The other main limitation of the model is the use of all
treatment regimens in the same population. All three iron
chelators have different indications in their SPCs; DFO is
indicated for all patients [12], DFX is indicated for all
patients C6 years old, or patients aged 2–5 years in whom
DFO is contraindicated or inadequate [17], while DFP is
indicated for all patients in whom DFO is contraindicated
or inadequate [15]. While these represent different popu-
lations, guidelines on the treatment of b-thalassaemia
indicate that regimens should be tailored to the needs of the
patient, rather than limiting their use to specific populations
[5]. For example, DFP and DFX monotherapy are both
recommended when adherence to DFO therapy is a con-
cern, with DFP specifically recommended in patients with
potentially dangerous cardiac iron levels [5]. Combination
therapy may be recommended in patients with high SFC
and LIC levels and ‘normal’ cardiac iron levels [5].
Treatment choices are therefore dependent on the likeli-
hood of compliance and the combination of SFC, LIC and
cardiac MRI T2*. Given the complexity of modelling these
different situations, and the absence of data to inform such
a model, it was consequently decided to use the overall
patient population.
The perspective used in the model was that of the UK
NHS, including personal and social services. The societal
perspective was not used due to a lack of data on pro-
ductivity gains/losses or absenteeism with the various
treatment regimens, and the consequent difficulty in
quantifying their effect on these outcomes. However, it is
highly likely that cardiac morbidity and mortality would be
the main factors influencing productivity in the b-thalas-
saemia population. As DFP has been shown to significantly
improve cardiac morbidity and mortality compared with
DFO [15], the exclusion of the societal perspective is likely
to bias the analysis against DFP.
The results of this study are consistent with an economic
model by Luangasanatip et al. [30], which evaluated the
cost effectiveness of DFP, DFX and DFO from a Thai
perspective. The analysis was performed using a Markov
model, as in the current analysis, and the same values were
used for the QoL decrement associated with DFO admin-
istration [30]. In the Thai study it was assumed that DFP,
DFX and DFO had equivalent efficacy for all outcomes;
however, the results indicated that DFP still dominated
DFX and DFO, as was found in our analysis.
Three other studies have examined the cost effectiveness
of DFX relative to DFO, two of which excluded DFP
monotherapy from the analysis [3, 28, 29]. Given that DFP
is likely to be used in a similar population in clinical
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practice, the exclusion of DFP in these studies means that
they do not represent the true cost effectiveness of the
interventions considered. These studies assumed that DFX
and DFO have equivalent efficacy, as in our analysis, but
did not include published AE rates. Karnon et al. [28]
found that DFX dominated DFO over a 1-year period in
their base case (mean patient weight 42 kg), and resulted in
an ICER of £7,775 when mean patient weight was assumed
to be 62 kg. A later study by Karnon et al. [29] considered
cost effectiveness over a lifetime, using the assumption that
the increased compliance afforded by oral treatment would
lead to a survival benefit. AEs were considered in the
analysis by Karnon et al., although rates for these were not
obtained from published literature, but were simulated
based on expected compliance. The Karnon study found
that DFX gave a cost saving of £72,089 over a patient
lifetime compared with DFO; however, the use of modelled
AE rates and an inferred survival benefit are not as robust
as those used in the current analysis, where published
evidence was used. Despite this, the sensitivity analyses
performed in the Karnon et al. [29] study resulted in a
maximum ICER of £12,166, indicating that DFX is still
likely to be cost effective over a lifetime, compared with
DFO. The current analysis found that DFP dominated both
DFX and DFO over a 5-year period, and would therefore
most likely result in cost savings against both DFX and
DFO over a patient lifetime, although this was not
modelled.
McLeod et al. [3] evaluated DFX, DFO and DFP in a
simple model as part of a UK HTA in all conditions
requiring regular transfusions, using a 1-year time horizon.
This group found that DFX was likely to be cost effective
compared with DFO, with an ICER of B£30,000 per
QALY. DFP was not assumed to provide any additional
health benefits; however, in the analysis where it was
assumed that DFP and DFX had equivalent efficacy, it was
found that DFX was not cost effective for any patient
compared with DFP [3]. Although this model considered all
three iron chelators, it did not compare DFP with DFO, did
not evaluate combination therapy, and used a much broader
patient population than the current model. Despite this, the
finding that DFP is cost effective compared with DFX is
consistent with the conclusions from the current study.
The results of this analysis are specific to the UK NHS;
however, they are likely to be applicable in most countries.
It is highly unlikely that the efficacy of the available reg-
imens, the utility associated with their administration, or
the incidence of AEs would vary between countries. In
contrast, the costs associated with each regimen (including
drug costs, management of AEs, and monitoring) would be
expected to vary. However, as DFP generated more QA-
LYs than DFO, DFX or DFO–DFP, it will always be the
dominant strategy unless it is more expensive than the
other treatment regimens. It is therefore likely that the
results of the model would be relevant in any countries
where DFP is less expensive than DFX (or priced similarly
to DFO).
The results of this analysis indicate that, from a UK
perspective, DFP monotherapy dominates DFX and DFO
monotherapy and combination therapy over a 5-year time
horizon. DFP is currently indicated for use in all patients
when DFO is inadequate; however, the high QoL burden
associated with DFO administration [13] and the conse-
quent implications for compliance mean that DFO therapy
may be inadequate for many patients. Adopting DFP in
these patients has been shown to confer a cardiac benefit
[16, 19–21] and, as shown in the current analysis, it may
also result in substantial cost savings compared with DFO
and DFX.
7 Conclusion
DFP appears to be the dominant treatment strategy from a
UK NHS perspective for chronic iron overload in b-thal-
assaemia patients; at a willingness-to-pay threshold of
£20,000 per QALY, there is a [99 % probability of DFP
being cost effective in all scenarios explored.
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